nach oben

vorheriger Artikel Tobacco control: prevention and cessation in Eu...

nächster Artikel Challenges in implementation of lung cancer scr...

Tipp

Whom to screen? A view on lung cancer screening from the pneumologist’s perspective

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 2/2019

Autoren:: Malte Asshoff, Günter Weiss, Ivan Tancevski

» Zum Volltext PDF-Version jetzt herunterladen

Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

The benefits of screening programs are highly dependent on risk group definition. This is especially true for lung cancer screening. Results from the National Lung Cancer Screening Trial (NLST) and the NELSON trial (Dutch/Belgian randomised lung cancer screening trial) demonstrated that lung cancer screening using low-dose CT scans results in reduction of cancer-related mortality. This article gives a short overview on participant selection in the NLST and NELSON trials, and on current evidence for implementation of multivariable risk prediction models.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Jetzt informieren

Stewart BW, Wild CP, editors. WHO world cancer report world cancer report. 2014.

WHO. Global health estimates. 2016. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.

Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. Thorax. 2013;68:551–64. CrossRef

National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409. CrossRef

DeKoning H, Van Der Aalst C, TenHaaf K, et al. Effects of volume CT lung cancer screening: mortality results of the NELSON randomized-controlled population based trial. World Conference on Lung Cancer; 25.9.2018. 2018. Abstract PL02.05.

Virginia A. Moyer, MD, MPH; on behalf of the U.S. Preventive services task force. Screening for lung cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2014;160(5):330–8.

Kovalchik S, Tammemagi M, Berg C, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013;369:245–54. CrossRef

Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007;99:715–26. CrossRef

Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95(6):470–8. CrossRef

10.

Knoke JD, Burns DM, Thun MJ. The change in excess risk of lung cancer attributable to smoking following smoking cessation: an examination of different analytic approaches using CPS-I data. Cancer Causes Control. 2007;19(2):207–19. CrossRef

11.

Meza R, Hazelton WD, Colditz GA, Moolgavkar SH. Analysis of lung cancer incidence in the nurses’ health and the health professionals’ follow-up studies using a multistage carcinogenesis model. Cancer Causes Control. 2008;19(3):317–28. CrossRef

12.

Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008;98:270–6. CrossRef

13.

Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368:728–36. CrossRef

14.

TenHaaf K, Jeon J, Tammemägi MC, et al. Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. Plos Med. 2017;4(14):e1002277. CrossRef

15.

Li K, Hüsing A, Sookthai D, et al. Selecting high-risk individuals for lung cancer screening: a prospective evaluation of existing risk models and eligibility criteria in the German EPIC cohort. Cancer Prev Res (Phila). 2015;8:777–85. CrossRef

16.

Weber M, Yap S, Goldsbury D, Manners D, Tammemagi M, et al. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCOm2012 risk prediction tool. Int J Cancer. 2017;141(2):242–53. CrossRef

17.

Raji OY, Duffy SW, Agbaje OF, et al. Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med. 2012;157:242–50. CrossRef

18.

Field JK, Duffy SW, Baldwin DR, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016;20:1–146. CrossRef

19.

AamliGagnat A, Gjerdevik M, Gallefoss F, Coxson HO, Gulsvik A, Bakke P. Incidence of non-pulmonary cancer and lung cancer by amount of emphysema and airway wall thickness: a community-based cohort. ERJ Open Res. 2017;49:1601162.

Titel: Whom to screen? A view on lung cancer screening from the pneumologist’s perspective
Autoren:: Malte Asshoff
Günter Weiss
Ivan Tancevski
Publikationsdatum: 05.06.2019
DOI: https://doi.org/10.1007/s12254-019-0501-x
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 2/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Publisher’s Note

Summary

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Weitere Artikel der Ausgabe 2/2019

Tobacco control: prevention and cessation in Europe

Response assessment in non-small cell lung cancer immunotherapy: initial experiences in utilizing FDG PET/CT and the PD-1 blocker nivolumab

Direct oral anticoagulants: a treatment option in oncological patients

Correction to: Seasonal fever for 11 years! A presentation of hemophagocytic lymphohistiocytosis secondary to marginal zone lymphoma

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

memo—publisher’s report 2018